PDGF Mutant Polypeptides for Enhanced PDGF and VEGF Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for PDGF variants with increased affinity for PDGF and VEGF receptors to effectively modulate signaling for therapeutic applications, as existing versions do not adequately target these receptors.
Innovation Solution
Isolated polypeptides with amino acid sequences comprising at least 70% of a wild-type PDGF or VEGF sequence, incorporating specific amino acid substitutions that enhance binding affinity to PDGF and VEGF receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type PDGF or VEGF is used, then the polypeptide maintains natural sequence and structure, but the binding affinity to PDGF and VEGF receptors is insufficient for effective therapeutic modulation
Solution Approach 1:
The patent applies parameter changes by modifying specific amino acid residues in the PDGF or VEGF polypeptide sequence to enhance binding affinity. Mutations such as E65K, R85K, and other substitutions are introduced to change the chemical properties of the polypeptide surface, increasing electrostatic interactions and hydrogen bonding with the receptor, thereby improving binding affinity without completely altering the overall structure.
Solution Approach 2:
The invention applies local quality by making targeted mutations at specific locations within the polypeptide sequence rather than uniformly modifying the entire structure. The mutations are concentrated in regions that contact the receptor (such as the basic domain and helical domain interfaces), leaving other regions unchanged to maintain overall structural integrity and natural folding.
2Reliability
If amino acid substitutions are introduced to enhance binding affinity, then receptor targeting improves, but the polypeptide structure deviates from wild-type sequence
Solution Approach 1:
The patent systematically changes amino acid parameters (charge, hydrophobicity, size) at specific positions to optimize binding. For example, introducing positively charged residues (Lysine, Arginine) at positions that contact negatively charged receptor surfaces enhances affinity while maintaining structural stability through conservative substitutions that preserve local secondary structure elements.
Solution Approach 2:
The mutations are localized to specific functional regions (basic domain, helical domain, receptor-binding interface) while preserving the overall tertiary structure. The polypeptide maintains at least 70% sequence identity to wild-type, ensuring that global structural stability is retained while local binding interfaces are optimized for higher affinity.
Data Source
AI summary
Isolated polypeptides having enhanced affinity for a PDGF receptor and/or a VEGF receptor are provided. Compositions comprising the polypeptides and methods of use thereof are also provided.